Serum perfluoroalkyl substances, vaccine responses, and morbidity in a cohort of guinea-bissau children by Timmermann, Clara Amalie Gade et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Serum perfluoroalkyl substances, vaccine responses, and morbidity in a cohort of
guinea-bissau children
Timmermann, Clara Amalie Gade; Jensen, Kristoffer Jarlov; Nielsen, Flemming; Budtz-
Jørgensen, Esben; van der Klis, Fiona; Benn, Christine Stabell; Grandjean, Philippe; Fisker,
Ane Bærent
Published in:
Environmental Health Perspectives
DOI:
10.1289/EHP6517
Publication date:
2020
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY
Citation for published version (APA):
Timmermann, C. A. G., Jensen, K. J., Nielsen, F., Budtz-Jørgensen, E., van der Klis, F., Benn, C. S., ... Fisker,
A. B. (2020). Serum perfluoroalkyl substances, vaccine responses, and morbidity in a cohort of guinea-bissau
children. Environmental Health Perspectives, 128(8), [087002]. https://doi.org/10.1289/EHP6517
Download date: 09. Oct. 2020
Serum Perfluoroalkyl Substances, Vaccine Responses, and Morbidity in a Cohort of
Guinea-Bissau Children
Clara Amalie Gade Timmermann,1 Kristoffer Jarlov Jensen,2,3 Flemming Nielsen,1 Esben Budtz-Jørgensen,4
Fiona van der Klis,5 Christine Stabell Benn,2,6 Philippe Grandjean,1,7 and Ane Bærent Fisker2,6,8
1Research Unit of Environmental Medicine, University of Southern Denmark, Odense, Denmark
2Research Center for Vitamins and Vaccines, Bandim Health Project, Statens Serum Institut, Copenhagen, Denmark
3Experimental and Translational Immunology, Department of Health Technology, Technical University of Denmark, Kgs Lyngby, Denmark
4Section of Biostatistics, University of Copenhagen, Copenhagen, Denmark
5Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, Netherlands
6Open Patient data Explorative Network, University of Southern Denmark/Odense University Hospital, Odense, Denmark
7Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA
8Bandim Health Project, Indepth Network, Bissau, Guinea-Bissau
BACKGROUND: Perfluoroalkyl substances (PFAS) are a group of widely used persistent chemicals with suspected immunotoxic effects.
OBJECTIVES: The present study aimed to examine the association between infant PFAS exposure and antibody responses to measles vaccination as
well as morbidity in a low-income country.
METHODS: In a randomized controlled trial, children from Guinea-Bissau, West Africa, were followed from inclusion (4–7 months of age) through
2 years of age. Half the children received two measles vaccinations (at inclusion and at 9 months of age), and the other half received only one
(at 9 months of age). In a subset of 237 children, six PFAS were quantified in serum at inclusion, and measles antibody concentrations were assessed
at inclusion and at approximately 9 months and 2 years of age. At inclusion and at the 9-month visit, mothers were interviewed about infant
morbidity.
RESULTS: All but one child had detectable serum concentrations of all six PFAS, although levels were lower than seen elsewhere. A doubling in per-
fluorooctane sulfonic acid (PFOS) and perfluorodecanoic acid (PFDA) were associated with 21% (95% CI: 2, 37%) and 25% (95% CI: 1, 43%),
respectively, lower measles antibody concentrations at the 9-month visit among the children who had received a measles vaccine at inclusion.
Elevated serum PFAS concentrations were also associated with reduced prevaccination measles antibody concentrations and increased morbidity.
DISCUSSION: The present study documents that PFAS exposure has reached West Africa and that infants show PFAS-associated increases in morbidity
and decreases in measles-specific antibody concentrations before and after vaccination. These findings support the evidence on PFAS immunotoxicity
at comparatively low serum concentrations. https://doi.org/10.1289/EHP6517
Introduction
Perfluoroalkyl substances (PFAS) are a group of persistent chemi-
cals produced since the 1940s and applied in industrial and com-
mercial products such as repellents for outdoor clothing, furniture
textiles, food packaging materials, cookware, and firefighting
foams (ATSDR 2018; Sunderland et al. 2019). Humans are
exposed to PFAS through contaminated food and water and
through inhalation and ingestion of dust (ATSDR 2018; Domingo
and Nadal 2017; Sunderland et al. 2019). Furthermore, PFAS are
transferred across the placenta and into breast milk (Manzano-
Salgado et al. 2015; Mogensen et al. 2015; Pan et al. 2017; Verner
et al. 2016), thereby causing peak exposures in infancy.
Due to their widespread use and resistance to breakdown,
PFAS are now globally distributed in the environment (Wang et al.
2017), and the presence of PFAS in humans and associations with
adverse health effects have been documented in numerous studies
from Asia, Europe, and North America (ATSDR 2018; Jian et al.
2018; Rappazzo et al. 2017). PFAS have been detected in the se-
rum of pregnant South African women (Hanssen et al. 2010) and
mothers in Tanzania (Müller et al. 2019), but little is known about
serumPFAS concentrations in African children.
Developmental exposure to PFAS has previously been associ-
ated with immunotoxicity in experimental models (DeWitt et al.
2019) and with increased morbidity risk (Dalsager et al. 2016;
Goudarzi et al. 2017; Granum et al. 2013; Impinen et al. 2018,
2019; Kvalem et al. 2020) and decreased antibody concentrations
after routine immunizations (Grandjean et al. 2012, 2017; Granum
et al. 2013; Stein et al. 2016) in children from Nordic countries,
Japan, and the United States. Based on estimated exposures, serum
PFAS concentrations in the first months of life are more important
predictors of subsequent reduced antibody concentrations than
PFAS concentrationsmeasured later in childhood (Grandjean et al.
2017), but studies of immunotoxicity relying on PFAS concentra-
tionsmeasured in infancy are lacking.
Although the <5 years of age mortality rate in West Africa
has declined by more than 50% since 1990, it is still at 9% with
infectious diseases being among the leading causes of death
(UNICEF 2019). Given the public health importance of success-
ful measles vaccination and the high incidence of infectious dis-
ease, the aim of the present study was to examine the association
between PFAS exposure in infancy and immune response to mea-
sles vaccination as well as morbidity among children in Guinea-
Bissau. We hypothesized that higher PFAS concentrations would
be associated with increased morbidity and decreased antibody
concentrations after vaccination. Furthermore, we examined the
association between PFAS concentrations and prevaccination
antibody concentrations.
Methods
This study is based on a subset of data from a randomized con-
trolled trial (RCT) of early measles vaccination conducted in
Guinea-Bissau from 2012 through 2015 (Fisker et al. 2018). The
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RCT compared two doses of measles vaccine (Edmonston-Zagreb
strain) at 4–7 and at 9months of age (intervention) vs. the usual sin-
gle measles vaccination at 9 months (control). Children living in
villages in three rural regions within a 2-h drive from the capital,
Bissau, were enrolled at 4–7months of age. At 9months of age, the
child was invited back for examination and measles vaccination.
The main outcome of the original trial was mortality until 3 years
of age. Furthermore, at inclusion and at the 9-month visit, mothers
were interviewed about child fever, diarrhea, coughing, and vomit-
ing on the day of the visit, in addition to duration of breastfeeding
and introduction of solids. Information about maternal education
and parity was obtained prior to enrollment through routine sur-
veillance data (Thysen et al. 2019). A subgroup study among 422
infants assessed measles antibodies using finger prick blood sam-
ples obtained at inclusion, at the 9-month visit, and at 2 years of
age. In the subgroup study, maternal blood samples were also
obtained at enrollment.We included in the present study those who
had measles antibodies measured at least once after receiving a
measles vaccination (n=242) and had sufficient serum from fin-
ger prick blood samples at inclusion to measure PFAS, thus
resulting in 237 included infants: 135 from the intervention group
and 102 from the control group (Figure 1). Measles IgG antibody
titers were measured at Rijksinstituut voor Volksgezondheid en
Milieu, Bilthoven, Netherlands, using a multiplex immunoassay,
as described by Smits et al. (2012).
Assessment of PFAS Exposure
PFAS analyses were conducted at the University of Southern
Denmark. The six types of PFAS usually found in measurable
concentrations in serum samples, that is, perfluorohexane sul-
fonic acid (PFHxS), perfluorooctane sulfonic acid (PFOS), per-
fluorooctanoic acid (PFOA), perfluorononanoic acid (PFNA),
perfluorodecanoic acid (PFDA), and perfluoroundecanoic acid
(PFUnDA) were quantified using online solid-phase extraction
followed by liquid chromatography and triple quadrupole mass
spectrometry, as described by Haug et al. (2009). The analysis
was performed on 75 lL serum from finger prick blood samples.
National Institute of Standards and Technology (NIST) Standard
Reference Material 1957 and NIST1958 samples as well as in-
house–made samples were included in the sample series for qual-
ity control. The between-batch imprecision was <13:8%, and the
limit of detection (LOD) was 0:03 ng=mL. Values below the
LOD were replaced by LOD/2. The accuracy of the PFAS meth-
ods are continuously secured by regular participation in the
German Quality Assessment program organized by the German
Society of Occupational Medicine.
One extreme PFNA value (16:24 ng=mL) was observed, and
serum was not available for duplicate analysis. We did not have
an explanation for this outlier and in order to avoid excessive
influence from this single measurement, it was excluded from the
statistical analyses.
Statistics
Associations between maternal/child characteristics and mater-
nal/child antibody concentrations were tested using the Wilcoxon
rank-sum test (binary variables) and the Kruskal-Wallis test
(>2 groups). The primary hypothesis of PFAS affecting the anti-
body response to measles vaccination was examined by testing the
associations between serum PFAS concentrations at inclusion and
antibody concentrations at the 9-month visit (intervention group
only) and the 2-y visit (both control and intervention group; groups
were analyzed separately) using linear regression. Furthermore,
we tested the association between PFAS and baseline levels of
measles antibodies at inclusion (both control and intervention
group) and at the 9-month visit (control group only) also using lin-
ear regression. Associations between PFAS and infant morbidity at
inclusion and at the 9-month visit were examined using logistic
regression models. Only 14 children vomited on the day of inclu-
sion, and only 9 children vomited on the day of the 9-month visit.
Vomiting on its own was, therefore, not used as an outcome in the
logistic regression models. However, fever, diarrhea, coughing,
and vomiting were combined into a new variable indicating
whether the child had had any of the four symptoms on the day of
the visit.
Distributions of child antibody and PFAS concentrations
were skewed to the right and were therefore log10 transformed
when included in the regression models in order not to violate
model assumptions and to avoid high values being overly influen-
tial. Estimates from the linear and logistic regression models
were back-transformed to express percentage difference in anti-
body concentrations and odds ratio (OR) of morbidity, respec-
tively, with a doubling in serum PFAS concentrations.
Potential confounding variables were identified using directed
acyclic graphs (DAGs) for the associations between PFAS and
measles antibody concentrations (Figure 2A) and between PFAS
and child morbidity (Figure 2B) based on a priori knowledge.
Maternal PFAS exposure have been shown to increase the risk of
preterm birth (Meng et al. 2018), and the placenta/maternal
serumPFAS ratiomight increase across gestation, thus perhaps sug-
gesting higher child PFAS exposure at increasing fetal age
(Mamsen et al. 2019). In addition, infants born preterm could have
an immature immune systemwith reduced ability to fight pathogens
and bacteria (Melville and Moss 2013), and preterm birth has been
associated with a reduction in transfer of maternal antibodies
(Okoko et al. 2001). Preterm birth could thus constitute a potential
confounder. Information about gestational length was, however, not
available, and weight (continuous to nearest 10 g) and age in days at
inclusion (continuous) were, therefore, used as a proxy for preterm
birth and included in the adjusted analyses.
Maternal education might affect child morbidity and child health
and thus indirectly the antibody concentrations. Furthermore, with
little knowledge about the routes of PFAS exposure in Guinea-
Bissau, we cannot exclude the possibility of socioeconomic status, as
reflected by maternal education, being associated with PFAS expo-
sure. Information about maternal education was, however, missing
for 10% of the participants, and in order not to reduce the sample size
when including this variable in the adjusted regression models, edu-
cationwas divided into three categories (any, none, and unknown).
Maternal PFAS concentrations have been associated with
reduced duration of breastfeeding among U.S. and Faroese moth-
ers (Romano et al. 2016; Timmermann et al. 2017), and breast-
feeding acts as an important pathway for PFAS exposure in
young children (Haug et al. 2011; Mogensen et al. 2015). In addi-
tion, breastfeeding is expected to have beneficial effects on theFigure 1. Overview of visits. Note: PFAS, perfluoroalkyl substances.
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immune system development (Plaza-Díaz et al. 2018) and reduce
child morbidity (Victora et al. 2016). Breastfeeding could, there-
fore, potentially act as a confounder in this study. In Guinea-
Bissau, virtually all children are breastfed during the first months
of life, and at inclusion, 43% of the children in our study had not
yet had porridge or other solid food introduced, whereas this was
the case for only 4% of the children at the 9-month visit.
However, 99% of the children were still being breastfed at
the 9-month visit. Consequently, analyses examining outcomes at
inclusion were adjusted for whether or not the child was still
being breastfed without complementary solids, whereas analyses
examining outcomes at the 9-month visit were adjusted for dura-
tion of breastfeeding without solids until 9 months (measured in
days), and analyses examining outcomes at the 2-y visit were
likewise adjusted for duration of breastfeeding without solids
(days).
Infant antibody concentrations prior to vaccination depend on
the maternal antibody concentrations (Niewiesk 2014), and if PFAS
are immunotoxic, themother’s exposure could affect her own serum
antibody concentrations. Furthermore, PFAS are transferred across
the placenta (Eryasa et al. 2019; Needham et al. 2011), and the
infant’s serum PFAS concentrations are thus affected by the mater-
nal PFAS concentrations. To avoid confounding from this backdoor
path, the analyses of measles antibody concentrations were adjusted
for thematernal antibody concentrations.
Analyses of the antibody concentration after vaccination were
first performed without adjustment for the child’s antibody concen-
tration prior to vaccination in order to explore overall effects on
postvaccination concentrations. We then carried out an analysis
with adjustment for the antibody concentration prior to the vaccina-
tion to elucidate whether PFASwere associated with a reduced abil-
ity to produce new antibodies upon vaccination. When adjusting for
Figure 2. Directed acyclic graphs for the hypothesized associations between child PFAS concentrations and (A) measles antibody concentrations or (B) child
morbidity. Arrows indicate a priori assumptions of associations. Dotted squares indicate unobserved variables. Note: PFAS, perfluoroalkyl substances.
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prevaccination antibody concentrations, maternal measles antibody
concentrations and preterm birth did not constitute potential con-
founders (Figure 2A), and maternal measles antibody concentra-
tions and the proxy variables weight and age at inclusion were,
therefore, not included in these analyses.
Pregnancies with male fetuses might have a higher placenta/
maternal serum PFAS ratio (Mamsen et al. 2019), which could
result in higher PFAS concentrations among boys compared with
girls. In addition, boys are more vulnerable to morbidity in infancy
(Zhao et al. 2017) and have been shown to have lower antibody
concentrations after measles vaccination with the Edmonston-
Zagreb strain (Martins et al. 2013). Child sex was thus included as
a potential confounder in the adjusted analyses of morbidity and
postvaccination antibody concentrations.
Postvaccination antibody concentrations depend on time since
vaccination, as the antibody concentration decrease over time. In
the present study, the interval between vaccination at inclusion
(intervention group) and blood sampling at the 9-month visit was
2.0–9.2 months (mean: 4.1) and the interval between the 9-month
vaccination/booster and blood sampling at the 2-y visit was 7.2–
23.6 months (mean: 15.4). Thus, to account for the variance in
time interval and improve model efficiency, the analyses of anti-
body concentrations after vaccination were adjusted for time
(days) since vaccination, in addition to the potential confounders
identified in the DAGs.
To sum up, four different sets of covariates were used for the
adjusted analyses; one set for analyses of prevaccination antibody
concentrations, one set for analyses of postvaccination antibody
concentrations without adjustment for prevaccination antibody con-
centrations, one set for postvaccination antibody concentrations
with adjustment for prevaccination antibody concentrations, and
one for set for morbidity analyses. The covariates included in each
model are listed in Tables 3 and 4.
In vitro data have shown that leukocytes obtained from adult
female donors were more sensitive to the toxic effects of PFAS
than were leukocytes from adult male donors (Corsini et al.
2012), and the development of the immune system may be de-
pendent on sex before puberty (Klein and Flanagan 2016). Thus,
we examined potential immunotoxic effects of PFAS exposure
separately for boys and girls. Sex-differential effects of PFAS on
measles antibody concentrations and child morbidity were tested
by including interaction terms in the regression models.
At inclusion, one child had a measles antibody concentration of
1,401mIU=mL (more than five times the 90th percentile for this
group). An elevated antibody concentration is likely due to prior
measles infection or unregistered measles vaccination, and the sin-
gle observation of 1,401mIU=mL was, therefore, excluded from
the analyses. Slightly outlying values were found for other children
as well, and to ensure that single points did not overly influence the
regression line, sensitivity analyses were performed excluding
highly influential observations from the linear regression models
[DFBETA>2=
ffiffiffiffi
N
p
] (Belsley et al. 1980). Up to 10 observations
were removed with an average of 4 observations per analysis (3%
of observations).
The assumptions underlying the linear regression models
about homoscedasticity and normal distribution of the resid-
uals were inspected visually using plots of residuals against
fitted values and quantile-normal plots of the standardized
residuals, respectively. Goodness-of-fit for the logistic regres-
sion models were tested using the Hosmer-Lemeshow test.
Log-linearity of PFAS was tested by including log(PFAS)
squared along with log(PFAS) in the regression model.
All analyses were performed using Stata/IC (version 16.1;
StataCorp). A 5% level of significance were used when testing
associations and interactions.
Ethics
The original trial was approved by the ethical review committee
in Guinea-Bissau (Comité Nacional de Etica na Saúde) and
received subsequent approval in Denmark [Danish Central
Ethical Committee (consultative approval)]. The trial was regis-
tered with ClinicalTrials.gov, Identifier: NCT01644721. The
present study relied on anonymized data and linked samples and,
therefore, did not require further approvals.
Results
At inclusion, the children were between 4.2 and 7.1 months
of age (mean: 5.6), at the 9-month visit between 8.9 and
18.2 months (mean: 9.9), and at the 2-y visit between 21.9 and
32.7 months (mean: 25.3). The intervals between PFAS measure-
ment at inclusion and the 9-month and 2-y visit were 2.0–12.1
months (mean: 4.3) and 16.4–25.6 months (mean: 19.5), respec-
tively. In the control group, the intervals between PFAS measure-
ment at inclusion and vaccination at the 9-month visit was
2.1–12.1 months (mean: 4.5).
One child had a serum PFUnDA concentration below the
LOD. All other children had detectable serum concentrations of
all six PFAS at inclusion. Median infant serum PFAS concentra-
tions ranged between 0:10 ng=mL (PFHxS) and 0:77 ng=mL
(PFOS). At inclusion, 20%, 11%, 30%, and 6% of the children
reportedly had current fever, diarrhea, coughing, and vomiting,
respectively, and at the 9-month visit, the corresponding frequen-
cies were 8%, 9%, 14%, and 3%. At inclusion, 42% reported any
Table 1. Distribution of PFAS concentrations, measles antibody concentra-
tions, and child morbidity.
Categories n
Median
(25th, 75th percentile)
or n (%)
PFAS (ng/mL serum)
PFHxS 237 0.10 (0.09, 0.14)
PFOS 237 0.77 (0.53, 1.02)
PFOA 237 0.68 (0.53, 0.92)
PFNA 236 0.21 (0.13, 0.31)
PFDA 237 0.19 (0.15, 0.25)
PFUnDA 237 0.12 (0.10, 0.16)
Measles antibody concentrations
(mIU/mL)
Maternal sample at inclusion 237 882 (412, 1,668)
Child at inclusion 236 54 (29, 124)
Child at 9-month visit
Control group 100 10 (6, 21)
Intervention group 134 432 (264, 749)
Child at 2-y visit
Control group 102 772 (441, 1,083)
Intervention group 92 577 (364, 1,102)
Reported child morbidity
Fever
At inclusion 236 47 (20)
At 9-month visit 236 19 (8)
Diarrhea
At inclusion 236 27 (11)
At 9-month visit 237 22 (9)
Coughing
At inclusion 236 71 (30)
At 9-month visit 237 32 (14)
Vomiting
At inclusion 235 14 (6)
At 9-month visit 237 8 (3)
Any morbidity
At inclusion 235 99 (42)
At 9-month visit 236 52 (22)
Note: PFAS, perfluoroalkyl substances; PFDA, perfluorodecanoic acid; PFHxS, per-
fluorohexane sulfonic acid; PFNA, perfluorononanoic acid; PFOA, perfluorooctanoic
acid; PFOS, perfluorooctane sulfonic acid; PFUnDA, perfluoroundecanoic acid.
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current morbidity and at the 9-month visit, 22% reported any cur-
rent morbidity (Table 1).
The protective serum concentration of measles antibodies is
not known for certain but is often set to 120mIU=mL (Chen et al.
1990; Cohen et al. 2007; Ratnam et al. 1995). At inclusion, 5% (12/
237) of mothers and 74% (176/237) of the children had measles
antibody concentrations below 120mIU=mL. At the 9-month visit,
99% (99/100) of children in the control group (with no previous
vaccination) and 10% (14/134) of children in the intervention
group (vaccinated at inclusion) were below 120mIU=mL, and at
the 2-y visit, 2% (2/102) of children in the control group (with one
previous vaccination) and 1% (1/92) of children in the intervention
group (with two previous vaccinations) were below 120mIU=mL.
Girls tended to have higher measles antibody concentrations
after vaccination compared with boys, but no difference was seen
prior to vaccination (Table 2). Neither maternal education, child
weight at inclusion, nor breastfeeding without solids at inclusion
were significantly associated with child measles antibody concen-
trations in crude analyses (Table 2).
Among the children who had received a measles vaccination
at inclusion (intervention group), a doubling in PFOS and
PFDA was associated with 21% [95% confidence interval (CI):
2, 37%] and 25% (95% CI: 1, 43%) lower measles antibody con-
centrations at the 9-month visit (adjusted analyses), and when
removing the most influential points DFBETA>2=
ffiffiffiffi
N
p
, the
same trend was seen for all six PFAS, although not significant
for PFHxS and PFOA (Table 3). When excluding the most in-
fluential points, the trend persisted through the 2-y visit,
although weakened and not statistically significant. Among the
children who received their first measles vaccination at the
9-month visit (control group), elevated PFAS concentrations at
inclusion was likewise associated with reduced measles anti-
body concentrations at the 2-y visit, but the associations were
significant (for PFHxS, PFOS, PFOA, and PFNA) only after re-
moval of the most influential points (Table 3).
Elevated concentrations of all six PFAS were associated with
lower measles antibody concentrations at inclusion, but the asso-
ciations were not statistically significant unless the most influen-
tial points were removed in the sensitivity analyses (Table 3).
Among the children who did not receive a vaccination at inclu-
sion (control group), the associations persisted at the 9-month
visit, but the association was significant only for PFOS, where a
doubling in serum PFOS was associated with a 27% (95% CI: 4,
44%) lower measles antibody concentration. Again, the associa-
tions were strengthened by removal of the most influential points
most pronounced for PFOS [40% (95% CI: 19, 56%)] and PFDA
[23% (95% CI: 8, 53%)] (Table 3).
When examining the associations between PFAS and morbid-
ity at inclusion and at the 9-month visit, most (35 of 48) analyses
showed increased odds of morbidity at higher serum PFAS con-
centrations at inclusion, although only a few of the associations
were statistically significant (Table 4). The effects were generally
more pronounced at the 9-month visit, and the strongest results
were seen for PFHxS and PFOA in relation to coughing and any
morbidity. At the 9-month visit, ORs for coughing in association
with a doubling of PFHxS and PFOA were 2.15 (95% CI: 1.17,
3.97) and 1.87 (95% CI: 1.02, 3.45), respectively, whereas ORs
for any morbidity were 1.82 (95% CI: 1.06, 3.11) and 2.02 (95%
CI: 1.20, 3.41), respectively (Table 4).
Most of the associations between PFAS and diarrhea and
morbidity at inclusion were positive (OR>1) for boys and nega-
tive (OR<1) for girls (see Table S1), but this trend did not persist
across all outcomes, and among the 78 interaction analyses, only
4 were statistically significant (see Tables S1–S2). PFDA was
associated with higher odds of diarrhea at inclusion in boys [OR
1.66 (95% CI: 0.76, 3.59)] and with lower odds in girls [OR 0.35
(95% CI: 0.10, 1.20)] (pinteraction = 0:04). Similarly, PFOS and
PFUnDA were associated with higher odds of any morbidity at
inclusion in boys and with lower odds of any morbidity in girls
(pinteraction = 0:04 and 0.03, respectively) (see Table S1). In
Table 2. Child measles antibody concentrations at inclusion and at the 9-month and the 2-y visit by maternal and child characteristics.
Maternal and child
characteristics n (%)
Measles antibody concentrations [mIU/mL median (25th, 75th percentile)]
Inclusion 9-month visit/control 9-month/intervention 2-y visit/control 2-y visit/intervention
(No measles
vaccination)
(No measles
vaccination)
(1 measles
vaccination)
(1 measles
vaccination)
(2 measles
vaccinations)
Maternal parity 235 (100)
0 34 (14) 32 (15, 93) 5 (3, 17) 535 (467, 978) 1,000 (797, 1,603) 1,059 (505, 1,146)
1–2 80 (34) 71 (31, 108) 11 (8, 19) 354 (166, 682) 630 (401, 962) 494 (301, 1,106)
3–4 61 (26) 55 (30, 153) 8 (6, 18) 471 (202, 758) 750 (292, 1,074) 684 (415, 1,146)
5–11 60 (26) 59 (32, 127) 10 (6, 25) 421 (295, 725) 839 (699, 1,093) 570 (345, 830)
p-Valuea 0.06 0.18 0.18 0.06 0.21
Maternal education 237 (100)
None 102 (43) 67 (34, 149) 12 (7, 22) 471 (295, 794) 735 (427, 1,058) 605 (373, 1,134)
1–11 y 111 (47) 49 (25, 96) 8 (5, 17) 396 (217, 687) 895 (471, 1,325) 570 (378, 1,100)
Missing 24 (10) 68 (28, 103) 10 (6, 18) 739 (188, 1,267) 590 (426, 893) 469 (330, 1,146)
p-Valuea 0.07 0.11 0.38 0.39 0.96
Child sex 237 (100)
Boy 123 (52) 58 (27, 136) 10 (6, 21) 376 (219, 749) 641 (398, 988) 570 (345, 891)
Girl 114 (48) 53 (29, 115) 9 (5, 21) 487 (317, 758) 871 (550, 1,401) 830 (390, 1,146)
p-Valueb 0.75 0.63 0.27 0.03 0.13
Child weight at
inclusion
237 (100)
<7 kg 131 (55) 53 (26, 137) 8 (5, 21) 532 (305, 765) 763 (427, 1,074) 562 (345, 1,018)
≥7 kg 106 (45) 58 (31, 100) 11 (7, 21) 375 (198, 745) 782 (442, 1,103) 601 (391, 1,146)
p-Valueb 0.73 0.16 0.13 0.96 0.67
Breastfeeding without
solids at inclusion
237 (100)
Yes 102 (43) 54 (30, 135) 10 (6, 21) 373 (219, 1,199) 913 (506, 1,389) 601 (347, 1,100)
No 135 (57) 55 (27, 111) 9 (6, 21) 467 (293, 699) 702 (426, 1,004) 570 (378, 1,103)
p-Valueb 0.71 0.80 0.90 0.07 0.98
aAssociations tested using the Kruskal-Wallis test.
bAssociations tested using the Wilcoxon rank-sum test.
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Table 4. Odds ratio (OR) for the presence of fever, coughing, diarrhea, and any morbidity at inclusion and at the 9-month visit with a doubling of serum PFAS
concentrations at inclusion.
Morbidity and PFAS
Inclusion 9-month visit
n/N OR (95% CI) n/N OR (95% CI)
Fever
PFHxS
Crude 47/236 1.29 (0.78, 2.14) 19/236 1.02 (0.47, 2.18)
Adjusteda 47/236 1.31 (0.78, 2.21) 19/236 0.95 (0.43, 2.08)
PFOS
Crude 47/236 1.30 (0.84, 2.00) 19/236 1.16 (0.62, 2.17)
Adjusteda 47/236 1.40 (0.90, 2.20) 19/236 1.19 (0.62, 2.31)
PFOA
Crude 47/236 0.96 (0.59, 1.56) 19/236 1.56 (0.77, 3.17)
Adjusteda 47/236 0.93 (0.56, 1.56) 19/236 1.62 (0.74, 3.54)
PFNA
Crude 47/235 1.28 (0.89, 1.84) 19/235 1.32 (0.77, 2.26)
Adjusteda 47/235 1.29 (0.89, 1.86) 19/235 1.20 (0.70, 2.07)
PFDA
Crude 47/236 1.54 (0.94, 2.52) 19/236 1.24 (0.61, 2.53)
Adjusteda 47/236 1.49 (0.89, 2.49) 19/236 1.16 (0.56, 2.44)
PFUnDA
Crude 47/236 1.27 (0.81, 1.99) 19/236 0.85 (0.41, 1.78)
Adjusteda 47/236 1.29 (0.81, 2.07) 19/236 0.71 (0.33, 1.54)
Coughing
PFHxS
Crude 71/236 1.33 (0.85, 2.10) 32/237 1.96 (1.13, 3.41)
Adjusteda 71/236 1.28 (0.81, 2.05) 32/237 2.15 (1.17, 3.97)
PFOS
Crude 71/236 1.04 (0.72, 1.50) 32/237 1.41 (0.85, 2.33)
Adjusteda 71/236 1.00 (0.69, 1.47) 32/237 1.54 (0.92, 2.59)
PFOA
Crude 71/236 1.07 (0.70, 1.64) 32/237 1.63 (0.92, 2.89)
Adjusteda 71/236 1.06 (0.69, 1.64) 32/237 1.87 (1.02, 3.45)
PFNA
Crude 71/235 1.05 (0.77, 1.42) 32/236 1.37 (0.89, 2.10)
Adjusteda 71/235 1.06 (0.78, 1.45) 32/236 1.34 (0.87, 2.07)
PFDA
Crude 71/236 0.79 (0.51, 1.24) 32/237 1.16 (0.65, 2.07)
Adjusteda 71/236 0.77 (0.49, 1.22) 32/237 1.17 (0.64, 2.14)
PFUnDA
Crude 71/236 0.94 (0.62, 1.42) 32/237 1.01 (0.59, 1.75)
Adjusteda 71/236 0.93 (0.60, 1.44) 32/237 1.00 (0.57, 1.75)
Diarrhea
PFHxS
Crude 27/236 1.16 (0.62, 2.19) 22/237 1.54 (0.83, 2.84)
Adjusteda 27/236 1.25 (0.65, 2.39) 22/237 1.58 (0.81, 3.09)
PFOS
Crude 27/236 1.03 (0.60, 1.75) 22/237 1.01 (0.56, 1.82)
Adjusteda 27/236 1.14 (0.66, 1.96) 22/237 1.20 (0.62, 2.31)
PFOA
Crude 27/236 1.07 (0.58, 1.98) 22/237 1.31 (0.67, 2.53)
Adjusteda 27/236 1.09 (0.56, 2.09) 22/237 1.54 (0.72, 3.29)
PFNA
Crude 27/235 0.97 (0.62, 1.51) 22/236 1.26 (0.77, 2.08)
Adjusteda 27/235 0.97 (0.63, 1.49) 22/236 1.22 (0.73, 2.03)
PFDA
Crude 27/236 1.13 (0.61, 2.10) 22/237 1.22 (0.62, 2.38)
Adjusteda 27/236 1.03 (0.54, 1.97) 22/237 1.17 (0.55, 2.51)
PFUnDA
Crude 27/236 0.99 (0.54, 1.79) 22/237 1.01 (0.53, 1.92)
Adjusteda 27/236 0.99 (0.53, 1.84) 22/237 0.91 (0.42, 1.94)
Any morbidityb
PFHxS
Crude 99/235 1.36 (0.87, 2.11) 52/236 1.76 (1.08, 2.88)
Adjusteda 99/235 1.32 (0.84, 2.07) 52/236 1.82 (1.06, 3.11)
PFOS
Crude 99/235 1.14 (0.81, 1.62) 52/236 1.25 (0.83, 1.89)
Adjusteda 99/235 1.13 (0.80, 1.62) 52/236 1.36 (0.88, 2.10)
PFOA
Crude 99/235 1.05 (0.71, 1.55) 52/236 1.81 (1.11, 2.93)
Adjusteda 99/235 1.03 (0.68, 1.54) 52/236 2.02 (1.20, 3.41)
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contrast, among those vaccinated at the 9-month visit only (con-
trol group), measles antibody concentrations at the 2-y visit were
22% higher in association with a doubling of PFOS in boys (95%
CI: –11, 66%) but were 28% lower in girls (95% CI: –48, –1%)
(pinteraction = 0:02) (Table S2).
For most of the linear regression models, plots of residuals
against fitted values and quantile-normal plots of standardized
residuals suggested that assumptions regarding homoscedasticity
and normal distribution of the residuals were met (data not
shown). Visual evidence of slight heteroscedasticity was dimin-
ished for PFAS and measles antibodies at inclusion, and in the
intervention group at the 9-month visit, when highly influential
observations DFBETA>2=
ffiffiffiffi
N
p
, 1.3–4.3% and 2.3–4.5% of obser-
vations, respectively) were removed in the sensitivity analyses.
In general, log(PFAS) squared was not significantly associated
with measles antibodies when added to the models, suggesting
that assumptions regarding log-linear associations were met in
most cases (data not shown). Exceptions were models of PFOA
and PFNA with measles antibodies at inclusion (p-values for
higher-order terms of 0.049 and 0.024, respectively). The devia-
tion was no longer significant for PFOA after 7 influential obser-
vations were removed (p=0:174) but remained significant for
PFNA (10 influential observations removed, p=0:047) with a
negative slope for PFNA concentrations <0:2 ng=mL (see Figure
S1). In the logistic regression models, the Hosmer-Lemeshow test
revealed a poor model fit when examining the associations
between PFHxS and coughing at the 9-month visit (p=0:029) and
between PFOS and any morbidity at the 9-month visit (p=0:024).
However, the model fit was acceptable in most of the analyses,
and we therefore chose not to change the DAG a posteriori.
Discussion
The present study extends the documentation on the distribution
of PFAS exposure to West African infants and reports evidence
of immunotoxicity even at low PFAS exposures. Data on infant
PFAS exposure is limited, but a recent study measuring PFOS
and PFOA in stored dried blood spots from newborns in Upstate
New York found median concentrations of 1.74 and 1:12 ng=mL,
respectively (Ghassabian et al. 2018), and it should be noted that
concentrations in whole blood are approximately half of those
measured in serum (Poothong et al. 2017). In Faroese children, at
18 months of age, median PFHxS, PFOS, PFOA, PFNA, and
PFDA concentrations in serum (Grandjean et al. 2017) were
between 1.5 (PFDA) and 24 (PFOS) times higher than concentra-
tions in the present study. In the 2013–2014 U.S. National Health
and Nutrition Examination Survey (NHANES), median serum
concentrations (in nanograms per milliliter) of PFHxS (0.74),
PFOS (3.41), PFOA (1.80), and PFNA (0.62) in children 3–5
years of age were also higher than those found in the present
study, whereas the median PFDA serum concentration was lower
(0:10 g=mL) (Ye et al. 2018). Thus, the children in this study
generally had lower serum PFAS concentrations than children in
other parts of the world, but notably, we found detectable levels
of five of the investigated substances in all serum samples ana-
lyzed, and PFUnDA was detected in all but one of the samples.
The sources of PFAS exposure in Guinea-Bissau are
unknown. The population is among the poorest in the world, and
exposure from consumer products such as new furniture and out-
door clothing is, therefore, expected to be minimal. However, the
diet in rural Guinea-Bissau includes fish caught in small lakes
and rivers, and in some of the villages also marine fish, which
could constitute a PFAS source along with potentially contami-
nated drinking water (Jian et al. 2017). In Faroese children,
PFUnDA has been shown to be a marker of marine food exposure
(Dassuncao et al. 2018), and interestingly, in the present study,
we found PFUnDA in concentrations slightly higher than PFHxS,
thus indicating possible exposure from sea food. To our knowl-
edge, there is no relevant industry in the area that could leak
PFAS to the environment.
PFAS and Postvaccination Antibodies
Despite the relatively low serum PFAS concentrations among
infants in the present study, we found that elevated concentra-
tions of PFOS and PFDA in the intervention group were signifi-
cantly associated with lower measles antibody concentrations at
the 9-month visit after vaccination at inclusion (4–7 months of
age). After removal of the most influential points, the same trend
was seen for all six PFAS. A similar trend was seen at the 2-y
visit among the children who were first vaccinated at the 9-month
visit (control group). These results correspond to previous find-
ings in Faroese 5- and 7-y-olds from two cohorts vaccinated
against tetanus and diphtheria (Grandjean et al. 2012, 2017) and
to the findings of decreased rubella antibodies after vaccination
in Norwegian 3-y-olds prenatally exposed to PFAS (Granum et al.
2013). The Norwegian study also showed a trend toward reduced
measles antibody concentrations with elevated concentrations of
PFHxS, PFOS, PFOA, and PFNA, but the associations were not
significant, possibly due to the small sample size (n=50)
(Granum et al. 2013). Recent studies have analyzed data on ado-
lescents in the cross-sectional 1999–2000 and 2003–2004
NHANES. Although one found no association between serum
PFAS concentrations and rubella antibodies among 1,012 12- to
18-y-olds (Pilkerton et al. 2018), the other found PFAS to be
associated with reduced concentrations of mumps and rubella,
although not measles, antibodies among 1,191 12- to 19-y-olds
Table 4. (Continued.)
Morbidity and PFAS
Inclusion 9-month visit
n/N OR (95% CI) n/N OR (95% CI)
PFNA
Crude 99/234 1.03 (0.77, 1.37) 52/235 1.26 (0.89, 1.79)
Adjusteda 99/234 1.03 (0.77, 1.38) 52/235 1.23 (0.86, 1.75)
PFDA
Crude 99/235 1.00 (0.67, 1.51) 52/236 1.24 (0.77, 2.00)
Adjusteda 99/235 0.98 (0.65, 1.49) 52/236 1.23 (0.75, 2.03)
PFUnDA
Crude 99/235 1.01 (0.69, 1.49) 52/236 0.99 (0.62, 1.56)
Adjusteda 99/235 0.99 (0.67, 1.47) 52/236 0.92 (0.57, 1.48)
Note: CI, confidence interval; PFAS, perfluoroalkyl substances; PFDA, perfluorodecanoic acid; PFHxS, perfluorohexane sulfonic acid; PFNA, perfluorononanoic acid; PFOA, per-
fluorooctanoic acid; PFOS, perfluorooctane sulfonic acid; PFUnDA, perfluoroundecanoic acid.
aAdjusted for weight (to nearest 10 g) and age (days) at inclusion, sex, maternal education (none/any/unknown), and breastfeeding without solids (inclusion: yes/no, 9-month visit:
duration in days).
bFever, diarrhea, coughing, or vomiting.
Environmental Health Perspectives 087002-8 128(8) August 2020
(Stein et al. 2016). However, the vaccination status of the U.S.
adolescents was unknown (Stein et al. 2016).
Mechanisms for potential immunotoxic effects of PFAS are
uncertain, but in experimental studies, PFAS have been reported
to suppress T-cell-dependent antibody responses in rodents
(DeWitt et al. 2019; Dong et al. 2009; Keil et al. 2008).
Furthermore, an in vitro study of human immune cells showed
that PFAS can affect nuclear factor (NF)-jB activation, with
PFDA and PFOS being more active than PFOA (Corsini et al.
2012), which is consistent with our findings.
PFAS and Prevaccination Antibodies
Findings from the present study also suggested that higher serum
PFAS concentrations were associated with lower measles anti-
body concentrations before vaccination. Prior to vaccination (or
infection), infants are dependent on measles antibodies trans-
ferred from the mother across the placenta mainly during third
trimester (Leuridan and Van Damme 2007). During the present
study there was no measles epidemics and we do not expect the
infants to have been exposed to measles infection. Lower infant
measles antibody concentrations prior to vaccination is thus a
sign of either reduced maternal measles antibody concentrations,
reduced placental transfer, or increased metabolization and, thus,
increased waning of the antibodies. Associations between PFAS
and prevaccination titers persisted after adjustment for the moth-
er’s measles antibody concentrations, suggesting that PFAS may
disrupt the transfer of maternal antibodies or increase the rate at
which they decline after birth. In the absence of prior studies on
this issue, interpretation of our findings is tentative at present.
Infants with low prevaccination antibodies tend to have a more
robust humoral response to vaccination (Niewiesk 2014). In the
present study, those with higher serum PFAS concentrations had
lower prevaccination antibodies. However, instead of higher post-
vaccination antibodies, PFAS were associated with lower postvac-
cination antibody responses. This suggests that PFAS exposure
may reduce the robust humoral response to vaccination that is typi-
cally observed in infants with low prevaccination antibodies.
PFAS and Infant Morbidity
We saw a consistent trend toward increased odds of morbidity
with higher serum PFAS concentrations. Although previous stud-
ies on child morbidity did not have access to serum PFAS con-
centrations in infancy, our findings are in line with findings from
Norwegian, Danish, and Japanese studies of early life PFAS ex-
posure and morbidity episodes during the first years of life
(Dalsager et al. 2016; Goudarzi et al. 2017; Granum et al. 2013;
Impinen et al. 2018, 2019). The first Norwegian study showed
that higher prenatal exposure to PFOA and PFNA was associated
with more episodes of the common cold in the first 3 y of life,
and higher prenatal exposure to PFOA and PFHxS was associ-
ated with more episodes of gastroenteritis (Granum et al. 2013).
The study from Denmark showed an increased risk of fever in 1-
to 4-y-olds at higher maternal pregnancy concentrations of PFOS
and PFOA (Dalsager et al. 2016). The study from Japan showed
increased odds of total infectious disease in the first 4 y of life at
higher prenatal exposure to PFOS (Goudarzi et al. 2017). The
second Norwegian study showed more lower respiratory tract
infections in the first 10 y of life with increasing cord serum con-
centrations of PFAS, including PFOS, PFOA, and PFNA
(Impinen et al. 2018), whereas a the third Norwegian study
showed associations between prenatal exposure to PFAS, includ-
ing PFOS, PFOA, and PFHxS, and bronchitis/pneumonia in the
first 3 y of life (Impinen et al. 2019). However, results were not
consistent across all outcomes (Impinen et al. 2019). In older
children, a recent Norwegian study found an increased risk of
lower respiratory tract infections between 10 and 16 years of age
with higher serum PFAS concentrations, including PFOS, PFOA
and PFNA, measured at 10 years of age (Kvalem et al. 2020).
However, at 16 years of age, a trend was seen toward a reduced
risk of common colds in the past 12 months with higher serum
PFAS concentrations at 10 years of age (Kvalem et al. 2020).
Furthermore, a Danish and a Japanese study found no associa-
tions between maternal serum concentrations of PFOS and PFOA
and hospitalizations due to infection in early childhood (Fei et al.
2010) and otitis media during the first 18 months of life (Okada
et al. 2012), respectively. However, the validity of the PFAS
measurements in the Danish cohort have been questioned (Bach
et al. 2015).
Sex-Specific Associations
Significant differences between boys and girls were found in only
4 of 78 regression analyses, thus our findings do not support dif-
ferences in the association between PFAS and serological vaccine
responses or morbidity by sex. Given the limited statistical power
of the present study, a minor sex-related difference in PFAS sus-
ceptibility is, of course, possible.
Sensitivity Analyses
For the linear regression models, sensitivity analyses were per-
formed excluding influential observations DFBETA>2=
ffiffiffiffi
N
p
, to
ensure that the associations were not driven by outlying values.
When removing the influential points, the negative associations
between PFAS and measles antibodies were strengthened, thus
supporting the notion that the associations were not merely
chance findings.
Strengths and Weaknesses
The present study was performed on a subset of data collected for
another purpose, and a main limitation of this opportunistic
approach was that information was not available about all poten-
tial confounding variables. Preterm birth could constitute a poten-
tial confounding path between child PFAS exposure and
prevaccination antibodies, but we did not have information about
gestational length. Instead, we adjusted for weight and age at
inclusion, which resulted in only a minor impact on the findings.
Information about morbidity was based on information from
the mother without clinical measures, and we did not have infor-
mation about the causes of fever, diarrhea, coughing, and vomit-
ing. Furthermore, past morbidity was not taken into account.
Nonetheless, the results from the morbidity analyses substantiate
the hypothesis of PFAS affecting the immune system.
Precision and accuracy of the methods used to assess PFAS
and measles antibodies were high, thus reducing the risk of infor-
mation bias. At inclusion, the serum PFAS concentrations and
morbidity outcomes were assessed simultaneously, whereas at
the 9-month visits, the time interval between exposure and out-
come assessment varied by 2–12 months. However, due to the
long half-life of the PFAS, the differences will probably not have
influenced the findings of the study to any substantial degree.
Similarly, variations in the interval between PFAS assessment
and vaccination in the control group (2–12 months) should matter
little. Measurements of the mothers’ antibody concentrations
were performed on average 5.6 months after childbirth, which
could introduce some imprecision and, thus, residual confound-
ing in the analyses adjusted for maternal antibody concentrations.
Information about PFAS exposure sources in Africa is
sparse, and the causal pathways hypothesized in the DAG may,
therefore, be insufficient. However, by adjusting for the most
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important predictors for the outcomes, we believe that the risk
of additional confounding is minimal. Furthermore, the living
conditions, nutritional intake, and health status of these children
is very different from other cohorts, where similar associations
between PFAS exposures and vaccine antibodies have been
found. It is, therefore, unlikely that any overlooked confound-
ing factors would be the same across the different settings in
this and previous studies.
Only children who had measles antibodies measured at least
once after receiving a measles vaccination were included in the
study. More children were thus included from the intervention
group than from the control group. However, because separate
analyses were performed for control and intervention children af-
ter vaccination, this selection should not have affected the results.
In this study, we examined six types of PFAS and five dif-
ferent outcomes at two or three time points. Thus, a few signif-
icant findings are to be expected merely by chance, and we
therefore focused on general trends in the data. Overall, our
findings are in agreement with the hypothesis of adverse
immune system effects of early life exposure to PFAS, even at
comparatively low exposure levels.
Most recently, the European Food Safety Authority (EFSA)
published a draft scientific opinion on PFAS, suggesting a low-
ered tolerable weekly intake of PFHxS, PFOS, PFOA, and PFDA
based on epidemiological evidence that PFAS have immunotoxic
effects (CONTAM Panel et al. 2020). The EFSA also emphasized
the need for more longitudinal epidemiological studies using dif-
ferent populations, examining infections and more varied types
of vaccines (CONTAM Panel et al. 2020). The present study
adds to the strength of the evidence suggesting that PFAS are
immunotoxic to infants even at lower serum concentrations than
previously examined.
Conclusions
In this study of West African children with low PFAS exposures,
a doubling of serum PFOS and PFDA concentrations in children
vaccinated at 4–7 months of age was associated with 21% (95%
CI: –37, –2%) and 25% (95% CI: –43, –1%) lower measles anti-
body concentrations (respectively) at approximately 9 months of
age. Furthermore, we saw a trend toward reduced measles anti-
body concentrations at 4–7 months of age (before vaccination)
and higher odds of morbidity with higher PFAS concentrations.
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